Magnetar Financial LLC boosted its holdings in shares of Organon & Co. (NYSE:OGN - Free Report) by 560.2% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 1,734,434 shares of the company's stock after buying an additional 1,471,731 shares during the period. Magnetar Financial LLC owned approximately 0.67% of Organon & Co. worth $25,878,000 as of its most recent SEC filing.
A number of other large investors have also recently made changes to their positions in the business. Prospera Private Wealth LLC bought a new stake in Organon & Co. during the third quarter worth $25,000. Horizon Bancorp Inc. IN grew its stake in shares of Organon & Co. by 2,401.5% in the 4th quarter. Horizon Bancorp Inc. IN now owns 1,651 shares of the company's stock worth $25,000 after acquiring an additional 1,585 shares in the last quarter. Larson Financial Group LLC raised its holdings in shares of Organon & Co. by 345.4% in the fourth quarter. Larson Financial Group LLC now owns 2,236 shares of the company's stock valued at $33,000 after purchasing an additional 1,734 shares during the last quarter. Riverview Trust Co raised its holdings in shares of Organon & Co. by 117.7% in the fourth quarter. Riverview Trust Co now owns 2,390 shares of the company's stock valued at $36,000 after purchasing an additional 1,292 shares during the last quarter. Finally, MassMutual Private Wealth & Trust FSB lifted its position in shares of Organon & Co. by 32.4% during the fourth quarter. MassMutual Private Wealth & Trust FSB now owns 2,749 shares of the company's stock valued at $41,000 after purchasing an additional 672 shares in the last quarter. 77.43% of the stock is owned by institutional investors.
Analyst Upgrades and Downgrades
OGN has been the subject of several analyst reports. Morgan Stanley decreased their price objective on shares of Organon & Co. from $17.00 to $16.00 and set an "equal weight" rating for the company in a research note on Friday, February 14th. Barclays decreased their price target on Organon & Co. from $26.00 to $24.00 and set an "overweight" rating for the company in a research report on Friday, February 14th. Finally, TD Cowen raised Organon & Co. to a "hold" rating in a research report on Wednesday, January 15th. One analyst has rated the stock with a sell rating, three have issued a hold rating, two have given a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat.com, Organon & Co. presently has a consensus rating of "Hold" and a consensus target price of $20.80.
Check Out Our Latest Stock Report on Organon & Co.
Organon & Co. Stock Performance
Organon & Co. stock traded down $0.05 during trading on Monday, hitting $15.35. The stock had a trading volume of 3,460,000 shares, compared to its average volume of 2,409,683. The stock's 50 day moving average is $15.44 and its two-hundred day moving average is $16.41. Organon & Co. has a 1 year low of $13.87 and a 1 year high of $23.10. The stock has a market cap of $3.96 billion, a price-to-earnings ratio of 4.61, a price-to-earnings-growth ratio of 0.90 and a beta of 0.76. The company has a quick ratio of 1.21, a current ratio of 1.70 and a debt-to-equity ratio of 17.73.
Organon & Co. (NYSE:OGN - Get Free Report) last issued its quarterly earnings results on Thursday, February 13th. The company reported $0.83 EPS for the quarter, missing analysts' consensus estimates of $0.92 by ($0.09). Organon & Co. had a net margin of 13.49% and a return on equity of 431.62%. The firm had revenue of $1.59 billion for the quarter, compared to analysts' expectations of $1.57 billion. As a group, analysts predict that Organon & Co. will post 3.68 EPS for the current year.
Organon & Co. Dividend Announcement
The firm also recently announced a quarterly dividend, which was paid on Thursday, March 13th. Stockholders of record on Monday, February 24th were paid a $0.28 dividend. The ex-dividend date of this dividend was Monday, February 24th. This represents a $1.12 annualized dividend and a dividend yield of 7.30%. Organon & Co.'s payout ratio is 33.63%.
Organon & Co. Profile
(
Free Report)
Organon & Co is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women's health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.
Read More
Before you consider Organon & Co., you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Organon & Co. wasn't on the list.
While Organon & Co. currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
